SciELO - Scientific Electronic Library Online

vol.15 issue3Tuberculous lymphadenitis in children: A systematic review of case reportsUsability of the virtual health care in the quarantine period from May to July 2020 due to COVID-19 at the National Institute of Child Health in Peru author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand




  • Have no cited articlesCited by SciELO

Related links

  • Have no similar articlesSimilars in SciELO


Revista del Cuerpo Médico Hospital Nacional Almanzor Aguinaga Asenjo

Print version ISSN 2225-5109On-line version ISSN 2227-4731


OSCANOA, Teodoro J.; AMADO-TINEO, José; MATTA-PEREZ, Javier  and  TAYPE-HUAMANI, Waldo. Previous use of angiotensin-II receptor blockers in hospitalized hypertensive patients and COVID-19 mortality. Rev. Cuerpo Med. HNAAA [online]. 2022, vol.15, n.3, pp.337-341.  Epub Sep 30, 2022. ISSN 2225-5109.


There is caurrently great interest in establishing the relationship between the severity of SARS-COV-2 infection in hypertensive patients who use angiotensin II antagonists (AIIRAs).


To study the relationship between the previous use of angiotensin II antagonists (ARB) in hypertensive patients and mortality from COVID-19.

Materials and methods:

A retrospective observational study was carried out in a tertiary care hospital in Lima, Peru, in hypertensive patients hospitalized in March 2021 for severe COVID-19.


A total of 101 patients entered the study, with a mean age of 70.1 + 12.0 and 48% male. ARB users and non-users were 45 (45.6%) and 56 (54.4%), respectively. The Charlson Comorbidity Index was higher in the ARB group (3.6 + 1.56 vs 3.04 + 1.24) (p<0.05). Total and male vs women mortality, among those using ARBs or not, were 57.8% vs 62% (p = 0.633) and 36.36% vs 63.64% (p <0.05), respectively. Mean lactate dehydrogenase concentration was lower in those taking ARBs compared to non-users, 394.18 + 152.3 vs 503.5 + 252.7 (p<0.05); No significant difference was observed in the leukocyte count and serum levels of C-Reactive Protein, Ferritin, D-dimer and fibrinogen.


Among hospitalized COVID-19 patients with hypertension, prior use of ARBSs was not associated with mortality risk.

Keywords : COVID-19, SARS-COV-2; hypertension, Angiotensin Receptor Antagonists; mortality.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )